Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
VYCOR MEDICAL INC (VYCO)
|
Add to portfolio |
|
|
|
| Price: |
$0.10
| | Metrics |
| OS: |
32.6
|
M
| |
|
|
| Market cap: |
$3.2
|
M
| |
|
|
|
Net debt:
|
$91.2
|
k
| |
|
|
|
EV:
|
$3.29
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| Revenues | 1.4 | 1.1 | 1.4 | 1.5 | 1.4 | 1.5 | 1.2 | 1.3 |
| Revenue growth | 22.0% | -18.0% | -7.7% | 9.0% | -6.8% | 27.5% | -6.8% | 12.1% |
| Cost of goods sold | 0.1 | 0.1 | 0.1 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 |
| Gross profit | 1.3 | 1.0 | 1.3 | 1.3 | 1.2 | 1.3 | 1.0 | 1.1 |
| Gross margin | 90.3% | 88.4% | 90.3% | 88.8% | 83.6% | 87.6% | 85.9% | 87.5% |
| Selling, general and administrative | 1.6 | 1.7 | 1.8 | 2.2 | | | | |
| Research and development | 0.0 | | | | 0.0 | 0.0 | 0.1 | 0.1 |
| General and administrative | | | | | 2.2 | 2.6 | 2.5 | 3.4 |
| EBITA | -0.4 | -0.7 | -0.6 | -1.0 | -1.2 | -1.5 | -1.9 | -2.6 |
| EBITA margin | -30.5% | -62.6% | -42.3% | -63.6% | -83.1% | -101.1% | -162.3% | -208.3% |
| Amortization of intangibles | 0.0 | 0.0 | 0.0 | 0.1 | 0.2 | 0.1 | 0.1 | 0.1 |
| EBIT | -0.4 | -0.7 | -0.6 | -1.0 | -1.3 | -1.6 | -2.0 | -2.7 |
| EBIT margin | -31.3% | -63.7% | -43.2% | -66.9% | -94.8% | -107.1% | -170.8% | -218.5% |
| Pre-tax income | -0.4 | -0.8 | -0.7 | -1.4 | -1.5 | -1.7 | -2.1 | -4.0 |
| Income taxes | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | | | | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Earnings from continuing ops | -0.7 | -1.1 | -1.0 | -1.7 | -1.8 | -1.8 | -2.3 | -4.0 |
| Earnings from discontinued ops | 0.0 | 0.0 | -0.1 | | | | | |
| Net income | -0.8 | -1.1 | -1.1 | -1.7 | -1.8 | -1.8 | -2.3 | -4.0 |
| Net margin | -54.6% | -100.4% | -80.4% | -112.9% | -130.1% | -123.3% | -193.0% | -323.9% |
| |
| Diluted EPS | ($0.02) | ($0.04) | ($0.04) | ($0.08) | ($0.10) | ($0.17) | ($0.21) | ($0.39) |
| Shares outstanding (diluted) | 29.6 | 26.1 | 24.0 | 21.6 | 18.4 | 11.1 | 10.8 | 10.3 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|